Arch Biopartners Cash Flow Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Net Income	-2.7	-1.55	-3.92	-3.33	-1.41	-1.17
Other Operating Activities	1.16	-0.03	1.59	3.09	1.89	-1.81
Operating Cash Flow	-1.53	-1.58	-2.33	-0.23	0.48	-2.98
Long-Term Debt Issued	-	0.34	0.35	1.5	-	2.2
Long-Term Debt Repaid	-	-	-0.21	-1.07	-0.79	-0.47
Net Debt Issued (Repaid)	-0.38	0.34	0.14	0.43	-0.79	1.73
Issuance of Common Stock	1.86	1.25	1.36	0.13	0.37	1.05
Financing Cash Flow	1.48	1.58	1.5	0.56	-0.42	2.78
Net Cash Flow	-0.05	-0	-0.83	0.32	0.06	-0.21
Cash Interest Paid	-	-	-	0	0.08	0.07
Levered Free Cash Flow	-0.76	-1.19	-1.29	0.68	0.61	-2.54
Unlevered Free Cash Flow	-0.59	-1.03	-1.05	0.91	0.8	-2.37

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.